74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Co-Diagnostics Inc
Closed
Sector Healthcare
0.69
Overview
Share price change
24h
Min
0.69
Max
0.7
Income | -2.1M -9.7M |
|---|---|
Sales | 480K 641K |
EPS | -0.32 |
Profit margin | -1,512.375 |
Employees | 155 |
EBITDA | -2.5M -9.9M |
Next Earnings | 13 Mar 2025 |
|---|
Market Cap | 22M |
|---|---|
Previous open | 0.69 |
Previous close | 0.69 |
News Sentiment
By Acuity
11%
89%
10 / 393 Healthcare
Technical Score
By Trading Central
Confidence
Weak Bullish Evidence
Co-Diagnostics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Co-Diagnostics Inc Forecast
Sentiment
By Acuity
10 / 393 Healthcare
News Sentiment
Very Strong Bullish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Co-Diagnostics Inc
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
